Last reviewed · How we verify

autologous bone marrow concentrate

Istituto Ortopedico Rizzoli · FDA-approved active Biologic Quality 5/100

Autologous bone marrow concentrate, marketed by Istituto Ortopedico Rizzoli, holds a unique position in the regenerative medicine space. The key composition patent, set to expire in 2028, provides a significant barrier to entry for competitors. However, the lack of clear primary indication and revenue data poses a strategic risk in assessing market potential and financial performance.

At a glance

Generic nameautologous bone marrow concentrate
SponsorIstituto Ortopedico Rizzoli
ModalityBiologic
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: